Strategy of anti-angiogenesis and antiangiogenic drugs in NSCLC

Journal of International Oncology ›› 2012, Vol. 39 ›› Issue (12): 916-920.

Previous Articles Next Articles

Strategy of anti-angiogenesis and antiangiogenic drugs in NSCLC

ZHAO Xiang-Fei, NIE Qing, KANG Jing-Bo

Department of Radio-Oncology, Navy General Hospital, Beijing 100048, China

Online:2012-12-08 Published:2012-11-15

Abstract

Abstract: Development and metastasis of NSCLC are closely related to angiogenesis. Several distinct groups of vascular – targeted therapies have evolved: anti-VEGF monoclonal antibody , Small Molecules, Vascular disrupting agents，Endothelial cell growth inhibitor，et al. Antiangiogenic treat could make longer survival than conventional treatment. The strategy of anti-angiogenic drugs combined conventional treatment is are being studied.

Key words: Carcinoma, non-small-cell lung, Angiogenesis, Molecular tergeted therapy

ZHAO Xiang-Fei, NIE Qing, KANG Jing-Bo. Strategy of anti-angiogenesis and antiangiogenic drugs in NSCLC[J]. Journal of International Oncology, 2012, 39(12): 916-920.

[1]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[2]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[3]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[4]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan. Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer [J]. Journal of International Oncology, 2021, 48(11): 660-665.
[5]	Qi Ruili, Wang Huaqing. Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors [J]. Journal of International Oncology, 2019, 46(12): 750-754.
[6]	Ke Bin, Li Bin, Liang Han. Research advances of EDIL3 in tumor [J]. Journal of International Oncology, 2019, 46(11): 678-681.
[7]	Feng Yue, Yu Jingping, Wang Jianlin. Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer [J]. Journal of International Oncology, 2017, 44(6): 468-.
[8]	WANG Mei, JIANG Xiao-Dong. The role of epigenetics on antiangiogenesis therapy [J]. Journal of International Oncology, 2017, 44(5): 380-382.
[9]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273.
[10]	Hou Xiaoyun, Chu Yanjun.. The mechanism of RNA interference for hepatocellular carcinoma treatment [J]. Journal of International Oncology, 2017, 44(4): 297-299.
[11]	FAN Ze-Ying, ZHANG Xiao-Dong, CHEN Hong-Qing. The mechanism of itraconazole as an anticancer agent [J]. Journal of International Oncology, 2017, 44(2): 136-138.
[12]	Qu Liyan, Kang Xiaoyan, Song Xia. Appliation of the combination of antiangiogenic agents and EGFR-TKIs in advanced NSCLC treatment [J]. Journal of International Oncology, 2017, 44(1): 57-59.
[13]	SUN Ning-Bo, WANG Wei, ZHU Qiang, CAO Ming, JIANG Zhong-Min, ZANG Qi. Inhibitory effect of dexamethasone on residual Lewis lung cancer cells in mice after palliative surgery [J]. Journal of International Oncology, 2016, 43(2): 81-.
[14]	SHANG Yi-Tai, LI Xiao-Jiang. Progress on antiangiogenesis treating head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2015, 42(8): 619-621.
[15]	Zhang Yuemeng, Sun Shanshan, Liu Wenzhi, Gao Wencang. Expression and effect of related factors of lymphangiogenesis in colorectal cancer [J]. Journal of International Oncology, 2015, 42(7): 542-544.

Strategy of anti-angiogenesis and antiangiogenic drugs in NSCLC

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments